Literature DB >> 30328149

Psoriasis is associated with a greater risk for cardiovascular procedure and surgery in patients with hypertension: A nationwide cohort study.

Hsien-Yi Chiu1,2,3,4, Wei-Lun Chang5, Ming-Neng Shiu5,6, Weng-Foung Huang5, Tsen-Fang Tsai3,4.   

Abstract

Psoriasis increases the incidence of hypertension and cardiovascular disease. However, its effect on the course of cardiovascular disease remains unknown. To investigate whether patients with psoriasis and hypertension have a higher requirement for cardiovascular procedure and surgery than patients with hypertension but without psoriasis, we used the Taiwan National Health Insurance Research Database to identify patients with new-onset hypertension during 2005-2006. Among these patients, those with psoriasis (n = 4039) were matched in a 1:1 ratio by age and sex with patients without psoriasis. The association between psoriasis and cardiovascular interventions was examined using time-varying Cox proportional hazards models. The mean follow-up period was 5.62 years. Psoriasis was associated with an increased risk for cardiovascular procedure and surgery in patients with hypertension (adjusted hazard ratio [aHR], 1.28; 95% confidence interval [CI], 1.07-1.53). When no psoriasis served as a reference group, the aHRs were higher for women than for men, and for patients aged 50-64 years than for younger and older patients. Patients with severe psoriasis or psoriatic arthritis tended to have higher risks of cardiovascular procedure and surgery than patients with mild psoriasis (aHR, 1.22; 95% CI, 0.98-1.51) or patients without psoriatic arthritis (aHR, 1.15; 95% CI, 0.84-1.58), respectively, did, although not reaching statistical significance. In conclusion, patients with hypertension and psoriasis had a greater requirement for cardiovascular interventions than hypertensive patients without psoriasis. More intense assessments for cardiovascular interventions may be necessary in patients with concurrent hypertension and psoriasis than general hypertension patients.
© 2018 Japanese Dermatological Association.

Entities:  

Keywords:  cardiovascular; hypertension; inflammation; procedure; psoriasis

Mesh:

Year:  2018        PMID: 30328149     DOI: 10.1111/1346-8138.14654

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  6 in total

1.  Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis.

Authors:  Gaku Tsuji; Akiko Hashimoto-Hachiya; Vu Hai Yen; Masaki Takemura; Ayako Yumine; Kazuhisa Furue; Masutaka Furue; Takeshi Nakahara
Journal:  Cell Death Discov       Date:  2020-03-04

Review 2.  Hypertension in connective tissue disease.

Authors:  Qiang Luo; Yiwen Zhang; Xiaoqian Yang; Li Qin; Han Wang
Journal:  J Hum Hypertens       Date:  2022-05-03       Impact factor: 3.012

Review 3.  Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.

Authors:  Tung-Lin Lee; Tsen-Fang Tsai
Journal:  Inflamm Res       Date:  2022-01-04       Impact factor: 4.575

4.  Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement.

Authors:  Tzong-Yun Ger; Yu-Huei Huang; Rosaline Chung-Yee Hui; Tsen-Fang Tsai; Hsien-Yi Chiu
Journal:  Ther Adv Chronic Dis       Date:  2019-04-17       Impact factor: 5.091

Review 5.  Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.

Authors:  Masutaka Furue; Akiko Hashimoto-Hachiya; Gaku Tsuji
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

6.  Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis.

Authors:  Gaku Tsuji; Akiko Hashimoto-Hachiya; Vu Hai Yen; Masaki Takemura; Ayako Yumine; Kazuhisa Furue; Masutaka Furue; Takeshi Nakahara
Journal:  Cell Death Discov       Date:  2020-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.